Skip to main
RZLT

Rezolute (RZLT) Stock Forecast & Price Target

Rezolute (RZLT) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rezolute Inc is making significant progress in developing therapies for rare metabolic diseases, notably congenital hyperinsulinism, with promising data indicating substantial reductions in hypoglycemia events, reflecting the effectiveness of their drug candidates. The positive results from the Phase 2b RIZE study, which showed a 70-90% reduction in weekly hypoglycemic events, and the 25% reduction reported in 10mg/kg ersodetug patients, underscore the potential for favorable patient outcomes that could lead to subsequent revenue generation. Furthermore, the favorable safety profile of ersodetug and the ongoing commitment to rigorous clinical research bolster Rezolute's prospects for successful regulatory approvals and market entry, aligning with the company’s strategic goal of addressing substantial unmet medical needs.

Bears say

Rezolute Inc is facing significant challenges following the disappointing results from its clinical trials, particularly with its lead candidate, Ersodetug, which did not demonstrate a statistically significant benefit compared to placebo, causing investor and company dismay. Additionally, the recent Phase 3 trial results for the sunRIZE study fell short of meeting key secondary endpoints, highlighting issues with the trial design and execution that may hinder the credibility of Rezolute's clinical efficacy claims. The biopharmaceutical company must navigate a landscape marked by standard industry risks, including unpredictable clinical outcomes and regulatory uncertainties, which, coupled with missed efficacy benchmarks, contribute to a negative outlook on its stock performance.

Rezolute (RZLT) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rezolute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rezolute (RZLT) Forecast

Analysts have given Rezolute (RZLT) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Rezolute (RZLT) has a Strong Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rezolute (RZLT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.